Uveal melanoma
MONDO:0006486A melanoma derived from melanocytes of the uveal tract. It is the most common primary intraocular tumor in the United States and Western Europe. Similar to melanoma of the skin, it is rare in Africa and Asia. Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound. Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection. Recent treatments also include radiotherapy or photo coagulation. Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types. The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.
Also known as: intraocular melanoma, melanoma (disease) of uvea, melanoma of the uvea, melanoma of uvea, melanoma, uveal, malignant, uvea melanoma, uvea melanoma (disease), uveal melanoma
2929 clinical trials for this condition and its sub-types, 98 tagged with Uveal melanoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Uveal melanoma
-
Malignant choroid melanoma 10 trials
5 sub-types
- Choroid epithelioid cell melanoma 0 trials
- Choroid mixed cell melanoma 0 trials
- Choroid necrotic melanoma 0 trials
- Choroid spindle cell melanoma 0 trials
- Intermediate cell type choroid melanoma 0 trials
-
Iris melanoma 4 trials
3 sub-types
- Intermediate cell type iris melanoma 0 trials Sub-types →
- Iris spindle cell melanoma 0 trials Sub-types →
- Malignant ciliary body melanoma 0 trials Sub-types →
-
Posterior uveal melanoma 0 trials · 3 incl. sub-types
2 sub-types
-
Epithelioid cell uveal melanoma 0 trials
2 sub-types
- Choroid epithelioid cell melanoma 0 trials
- Ciliary body epithelioid cell melanoma 0 trials
-
2 sub-types
-
Mixed cell uveal melanoma 0 trials
2 sub-types
- Choroid mixed cell melanoma 0 trials
- Ciliary body mixed cell melanoma 0 trials
-
Necrotic uveal melanoma 0 trials
1 sub-type
- Choroid necrotic melanoma 0 trials
-
Spindle cell intraocular melanoma 0 trials
2 sub-types
- Choroid spindle cell melanoma 0 trials
- Iris spindle cell melanoma 0 trials Sub-types →
Most studied deeper sub-types
-
Radioactive drug targets Hard-to-Treat melanoma in early trial
Disease control Stopped earlyThis early-stage trial tests a radioactive drug called [225Ac]Ac-A9-3408 in 50 adults with melanoma that has spread or can't be removed by surgery. The main goals are to find a safe dose and check for side effects. Participants receive the drug every 6 weeks for up to 6 doses, an…
Phase 1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a drug duo tame a rare eye cancer that has spread?
Disease control Stopped earlyThis trial is testing whether combining two drugs—pembrolizumab and lenvatinib—can help people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. Participants receive both drugs for up to two years. The study measures how long people liv…
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental drug BVD-523 tested for rare eye cancer, but trial stopped early
Disease control Stopped earlyThis study tested a drug called BVD-523 (Ulixertinib) in 13 people with advanced uveal melanoma, a rare eye cancer that has spread. The drug works by blocking certain proteins that help cancer grow. The trial was terminated early, so results are limited and it's unclear how well …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Engineered virus takes on Hard-to-Treat melanoma
Disease control Stopped earlyThis early-stage trial tested a modified virus (VSV-IFNbetaTYRP1) in 12 patients with advanced melanoma that had spread or could not be removed by surgery. The virus was designed to infect and kill melanoma cells while also boosting the immune system's attack. The main goals were…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Radioactive 'Smart Bomb' for tumours tested in early trial
Disease control Stopped earlyThis early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…
Phase 1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental cancer drug KZR-261 tested in early trial
Disease control Stopped earlyThis early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…
Phase 1 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Liver-Directed drug combo shows promise for rare eye cancer
Disease control Stopped earlyThis study tested a new drug called SD-101, given directly into the liver through a special pressure-enabled infusion, alone or with standard immunotherapy drugs. It was for adults with a rare eye cancer (uveal melanoma) that had spread mainly to the liver. The main goals were to…
Phase 1 • Sponsor: TriSalus Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Promising combo for eye cancer stalls after only 3 patients enrolled
Disease control Stopped earlyThis phase II trial tested a combination of precise radiation therapy followed by injections of aflibercept (Eylea) in people with uveal melanoma, a rare eye cancer. The goal was to see if this approach could control the tumor while reducing side effects like swelling or damage t…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC